The best-known CJC-1295 human studies appear to have used the DAC form and measured short-term growth-hormone and IGF-1 changes in healthy adults. Ipamorelin studies measured an acute growth-hormone response or postoperative gastrointestinal recovery, not general body-composition or wellness outcomes. As of September 11, 2026, FDA records distinguish DAC from non-DAC forms, list CJC-1295 and ipamorelin-related substances among compounding safety concerns, and do not turn marketed combination claims into clinical evidence.
Start with the molecule, not the label
CJC-1295 is described as an analogue of growth-hormone-releasing hormone (GHRH)—a lab-made molecule modeled on a natural signal that prompts the pituitary gland to release growth hormone (GH). The name can hide an important chemical distinction. CJC-1295 DAC contains a Drug Affinity Complex (DAC), an added structure that can bind the peptide to albumin in the blood and extend its persistence. FDA's 2024 review treated CJC-1295 without DAC and CJC-1295 DAC as distinct active moieties, along with their different salt forms, and noted inconsistent naming in nominations and public sources.[2]
Ipamorelin is a synthetic growth-hormone secretagogue—a substance that prompts hormone release—acting as a ghrelin-receptor agonist. A receptor is a cell feature that responds to a signal. In simple terms, CJC-1295 DAC and ipamorelin engage the GH axis through different signaling routes, so a study of one is not automatically evidence for the other. The comparison below uses the named forms and populations in the cited sources; it does not treat a product label such as “CJC-1295 no DAC” or “mod GRF” as proof that the DAC molecule was used.[2][6]
What the CJC-1295 DAC studies measured
The principal published CJC-1295 human study was a pair of randomized, placebo-controlled, double-blind trials in healthy adults ages 21 to 61. Randomized means participants were assigned by chance; placebo-controlled means one group received an inactive comparison; double-blind means participants and investigators did not know the assignment during the study. The researchers measured pharmacokinetics—how the body handles a substance—and GH and insulin-like growth factor 1 (IGF-1) concentrations. After CJC-1295 exposure, GH and IGF-1 remained changed for days, and repeated exposure kept mean IGF-1 above baseline for part of the follow-up.[4]
A separate clinical study in healthy young men used frequent overnight blood sampling. It found higher trough and mean GH and higher IGF-1 while the pattern of GH pulses was preserved. These are hormone and pharmacology endpoints, not measurements of fat, lean mass, physical function, disease symptoms, or long-term health. A hormone concentration can show that a biological pathway was engaged without showing that a person will experience a meaningful health outcome.[5]
FDA's CJC-1295 review found three human publications in healthy adults and said the exact form was not always clear, although the active moiety appeared to be CJC-1295 DAC (free base) without a specified salt. The review found no human studies establishing effectiveness for growth-hormone deficiency. That distinction is important: the published hormone response is evidence about the studied research compound and setting, not a clinical outcome claim for every item sold under a CJC-1295 name.[2]
What the ipamorelin studies measured
The human pharmacology study of ipamorelin enrolled healthy male volunteers and measured drug concentrations and GH. It described a single episode of GH release after exposure, with a short terminal half-life in that study. It did not test body composition, exercise performance, recovery, healthy aging, or a long-term clinical outcome. The result therefore shows acute pharmacology, not a demonstrated general health benefit.[6]
A different phase 2 proof-of-concept study—a mid-stage trial asking whether an approach might work—enrolled 117 adults in the hospital after small- or large-bowel resection. It compared ipamorelin with placebo for postoperative ileus, the temporary slowing of bowel movement after surgery. The key endpoint was time to tolerate a standardized solid meal; the publication reported no significant difference between groups in its key or secondary efficacy analyses. A surgical inpatient result cannot answer a question about body composition in otherwise healthy adults.[7]
FDA's 2024 ipamorelin briefing likewise concluded that the volunteer study supplied pharmacokinetic and pharmacodynamic information, not evidence for diagnosing or treating growth-hormone deficiency. FDA also described missing characterization information for the evaluated substances, including impurities, aggregates, and bacterial endotoxins. The current FDA safety page identifies limited clinical data and potential immunogenicity and peptide-quality concerns for compounded CJC-1295 and ipamorelin-related substances; that is a regulatory safety warning, not evidence of a particular outcome in every preparation.[1][9]
Visit the store directly, or keep exploring the evidence library. No email signup is needed to visit the store.
What the U.S. regulatory record says
As of September 11, 2026, FDA's current page for bulk substances that may present significant safety risks places CJC-1295 in its Category 2 interim-policy table. The page identifies possible immunogenicity, peptide-related impurities, and active-pharmaceutical-ingredient characterization problems, reports serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction, and says available clinical data are limited. FDA's current page also lists ipamorelin acetate with potential compounding risks. A Category 2 listing is not an FDA approval, an efficacy finding, or a guarantee that every preparation is identical.[1]
In its November 15, 2024 CJC-1295 briefing, FDA evaluated CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate. FDA stated that none was a component of an FDA-approved drug and that no applicable USP or National Formulary drug-substance monograph was available. At the December 4, 2024 advisory-committee meeting, the committee voted against adding each evaluated CJC-1295 form to the 503A bulk list; the summary minutes were approved on February 21, 2025. Those minutes record committee advice, not a final FDA determination.[2][3]
The August 19, 2024 FDA ipamorelin briefing similarly stated that ipamorelin free base and ipamorelin acetate were not components of an FDA-approved drug. It proposed against adding them to the 503A bulk list after reviewing the limited effectiveness and safety information. This is more precise than saying that no compounded product can exist: compounding status, product availability, FDA approval, and evidence of benefit are different questions.[9]
Why no-DAC and combination claims need separate evidence
Online product descriptions may use “CJC-1295 no DAC,” “mod GRF,” or a CJC-1295–ipamorelin blend. FDA's CJC review found inconsistent names and said that some public product listings did not make clear whether the CJC-1295 had DAC or which salt form was present. The review's human evidence appears to concern CJC-1295 DAC, while it found no human effectiveness studies for CJC-1295 free base without DAC. A marketed name is therefore not a bridge from DAC hormone data to a no-DAC or mod-GRF product.[2]
The FDA review also noted online listings for CJC-1295 combined with ipamorelin, but the listings did not establish the CJC form or provide a controlled clinical comparison. The cited human studies tested the substances separately, in different settings, with different endpoints. No cited trial compares CJC-1295 with ipamorelin head-to-head, and no cited trial establishes that their combination improves a patient-important outcome over either substance alone.[2][4][6][7]
A ClinicalTrials.gov record for a CJC-1295 study in people with HIV-associated visceral obesity is marked terminated, last updated in 2006, and has no results posted. It is not a CJC-1295-versus-ipamorelin trial and cannot supply a result that the registry does not report. The absence of a posted head-to-head result is why this brief describes different evidence bases rather than ranking the two substances.[8]
The useful bottom line
CJC-1295 DAC has human evidence that it can change GH and IGF-1 measurements for longer than a short pulse in healthy adults. Ipamorelin has human evidence of an acute GH response and a separate postoperative study that did not show significant efficacy differences from placebo. Neither evidence base establishes a general body-composition, performance, recovery, longevity, or wellness benefit, and the studies do not justify transferring DAC findings to every no-DAC or mod-GRF product.[2][4][5][6][7]
The fairest comparison is therefore a map of what was studied, not a treatment scorecard. Before accepting a claim, ask which exact form was tested, who participated, what the comparator was, whether the endpoint was a hormone measurement or a patient-important outcome, and whether the regulatory document is a current FDA action or a dated advisory review. Those questions preserve the useful signal in the science without converting mechanism or marketing into a promise.[1][2][4][6][9]
At a glance
| Topic | CJC-1295 | Ipamorelin |
|---|---|---|
| Form identified in the strongest cited human evidence[2][4][6][7] | The published studies measured CJC-1295, and FDA's review says the active moiety appears to have been CJC-1295 DAC free base, although the exact salt or form was not always specified. | The cited volunteer study measured ipamorelin pharmacokinetics and GH response; the postoperative trial evaluated ipamorelin against placebo in a surgical setting. |
| Human populations[5][7][8] | Healthy adults, including healthy young men in a GH-pulsatility study; a separate registered HIV-visceral-obesity study was terminated with no results posted. | Healthy male volunteers for pharmacology, and hospitalized adults after bowel resection for postoperative ileus. |
| What was measured[4][5][6][7] | GH and IGF-1 concentrations, GH pulsatility, and pharmacokinetic measures—not a long-term health outcome. | Drug concentrations and an acute GH episode in volunteers; time to tolerate a standardized meal and safety in the postoperative study. |
| Evidence for healthy-adult body-composition or wellness outcomes[2][4][6][7] | Not established by the cited hormone studies; results do not automatically apply to no-DAC or mod-GRF labels. | Not established by the cited volunteer pharmacology or postoperative-ileus study. |
| Current U.S. regulatory context[1][2][3][9] | FDA's current Category 2 safety page lists CJC-1295; a 2024 FDA review found no evaluated form was a component of an FDA-approved drug, and the 2024 committee advised against 503A-list inclusion. | FDA's current safety page lists ipamorelin acetate; a 2024 FDA briefing found neither ipamorelin free base nor acetate was a component of an FDA-approved drug. |
| Head-to-head or combination evidence[2][4][6][7][8] | No cited head-to-head trial with ipamorelin; combination listings do not identify a controlled clinical outcome. | No cited head-to-head trial with CJC-1295; separate ipamorelin studies cannot validate a combination claim. |
Questions readers ask
Is CJC-1295 the same molecule as CJC-1295 DAC?
No. FDA's 2024 review treats CJC-1295 without DAC and CJC-1295 DAC as distinct active moieties, with additional salt forms considered separately. The best-known human CJC-1295 studies appear to involve the DAC active moiety, so their results should not automatically be assigned to a no-DAC or mod-GRF product.[2][4]
Do CJC-1295 DAC studies prove a health benefit?
No. The central studies measured GH, IGF-1, GH pulsatility, and pharmacokinetics in healthy adults. Those are biological or laboratory endpoints; the cited studies did not establish a general body-composition, performance, recovery, longevity, or wellness outcome.[4][5]
What did human ipamorelin studies actually show?
A healthy-volunteer study measured drug levels and an acute episode of GH release. A separate phase 2 study in adults recovering from bowel resection found no significant difference from placebo in its key or secondary efficacy analyses. Neither study answers a healthy-adult body-composition question.[6][7]
Does a “no-DAC” or “mod GRF” label carry over the DAC evidence?
Not on the cited evidence. FDA documented inconsistent naming and uncertainty about which CJC form appeared in public product listings. A product label does not establish that the DAC molecule, salt form, purity, exposure, or clinical evidence is the same as in the published research.[2]
Is the CJC-1295 and ipamorelin combination clinically proven?
No cited clinical trial compares the combination with either substance alone for a patient-important outcome, and no cited head-to-head trial compares CJC-1295 with ipamorelin. FDA's review noted online combination listings, but a listing is not a controlled clinical study and did not resolve which CJC form was present.[2][4][6][7]
Sources
References
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration current Category 2 interim-policy page, accessed September 11, 2026; CJC-1295 and ipamorelin acetate safety-risk entries and limited-clinical-data language.
- FDA Evaluation of CJC-1295-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances ListFDA Pharmacy Compounding Advisory Committee briefing dated November 15, 2024; DAC/non-DAC distinctions, inconsistent naming, reviewed human evidence, approved-drug status, and effectiveness and safety limits.
- Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024FDA summary minutes approved February 21, 2025; committee votes against placing the evaluated CJC-1295 free-base, acetate, DAC, DAC acetate, and DAC trifluoroacetate forms on the 503A Bulks List. Advisory minutes are not a final FDA determination.
- Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy AdultsTeichman et al., Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805; randomized placebo-controlled healthy-adult pharmacokinetic, GH, and IGF-1 study.
- Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone AnalogIonescu and Frohman, Journal of Clinical Endocrinology & Metabolism, 2006;91(12):4792–4797; healthy young men, overnight sampling, GH pulsatility, and IGF-1 endpoints.
- Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone-Releasing Peptide, in Human VolunteersGobburu et al., Pharmaceutical Research, 1999;16(9):1412–1416; healthy male volunteer pharmacokinetic and acute GH pharmacodynamic study.
- Prospective, Randomized, Controlled, Proof-of-Concept Study of the Ghrelin Mimetic Ipamorelin for the Management of Postoperative Ileus in Bowel Resection PatientsBeck et al., International Journal of Colorectal Disease, 2014;29(12):1527–1534; phase 2 placebo-controlled inpatient trial with 117 enrolled adults and no significant key or secondary efficacy differences.
- A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527)ClinicalTrials.gov record supplied by ConjuChem; status terminated, last update posted October 16, 2006, with no results posted. The registry record is not a head-to-head or combination result.
- FDA Evaluation of Ipamorelin-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances ListFDA Pharmacy Compounding Advisory Committee briefing dated August 19, 2024; approved-drug status, pharmacology versus effectiveness limits, characterization gaps, and proposed 503A-list recommendation.